Augere Medical
Augere Medical is a medical technology company commercializing the PolypAID™ platform, an AI-assisted colonoscopy guidance system designed to improve detection of adenomas, sessile serrated lesions, and hyperplastic polyps in the colon. The company leverages over five years of research and collaboration with leading hospitals in Norway and Sweden to develop a highly accurate AI system with high sensitivity and specificity, reducing false positives compared to competitors. Augere Medical focuses on quality, agility, and delivering results, targeting colorectal cancer screening programs to reduce cancer incidence and mortality. The company has secured CE MDR approval for its AI technology and has begun commercial use in hospitals, including the first use in Germany. Augere operates with a business model based on sales and partnerships with hospitals and healthcare providers, supported by public grants and private investors. The company is led by a team with deep expertise in medical technology, AI, and clinical gastroenterology, and maintains strong partnerships with research institutions and healthcare organizations.
Augere Medical
Augere Medical is a medical technology company commercializing the PolypAID™ platform, an AI-assisted colonoscopy guidance system designed to improve detection of adenomas, sessile serrated lesions, and hyperplastic polyps in the colon. The company leverages over five years of research and collaboration with leading hospitals in Norway and Sweden to develop a highly accurate AI system with high sensitivity and specificity, reducing false positives compared to competitors. Augere Medical focuses on quality, agility, and delivering results, targeting colorectal cancer screening programs to reduce cancer incidence and mortality. The company has secured CE MDR approval for its AI technology and has begun commercial use in hospitals, including the first use in Germany. Augere operates with a business model based on sales and partnerships with hospitals and healthcare providers, supported by public grants and private investors. The company is led by a team with deep expertise in medical technology, AI, and clinical gastroenterology, and maintains strong partnerships with research institutions and healthcare organizations.